Comparison of Sinemet CR4 and standars Sinemet: double blind and long-term open trial in Parkinsonian patients with fluctuations
Identifieur interne : 006507 ( Main/Exploration ); précédent : 006506; suivant : 006508Comparison of Sinemet CR4 and standars Sinemet: double blind and long-term open trial in Parkinsonian patients with fluctuations
Auteurs : Joseph Jankovic [États-Unis] ; K. Schwartz ; C. Vander LindenSource :
- Movement disorders [ 0885-3185 ] ; 1989.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
More sustained plasma levodopa levels may be achieved with a new controlled-release formulation of carbidopa/levodopa, Sinemet CR4. We studied 20 patients, with Parkinson's disease complicated by «wearing-off» phenomenon. In a 12-week double-blind study, the average number of tablets administered per day decreased from 5.7±1.2 to 3.8±0.7 when Sinemet CR4 (50/200) was substituted for the standard Sinemet (25/100)
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 003A26
- to stream PascalFrancis, to step Curation: 002D99
- to stream PascalFrancis, to step Checkpoint: 003A09
- to stream Main, to step Merge: 009871
- to stream Main, to step Curation: 006507
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Comparison of Sinemet CR4 and standars Sinemet: double blind and long-term open trial in Parkinsonian patients with fluctuations</title><author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J." last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author><author><name sortKey="Schwartz, K" sort="Schwartz, K" uniqKey="Schwartz K" first="K." last="Schwartz">K. Schwartz</name></author><author><name sortKey="Vander Linden, C" sort="Vander Linden, C" uniqKey="Vander Linden C" first="C." last="Vander Linden">C. Vander Linden</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">90-0045470</idno><date when="1989">1989</date><idno type="stanalyst">PASCAL 90-0045470 INIST</idno><idno type="RBID">Pascal:90-0045470</idno><idno type="wicri:Area/PascalFrancis/Corpus">003A26</idno><idno type="wicri:Area/PascalFrancis/Curation">002D99</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003A09</idno><idno type="wicri:doubleKey">0885-3185:1989:Jankovic J:comparison:of:sinemet</idno><idno type="wicri:Area/Main/Merge">009871</idno><idno type="wicri:Area/Main/Curation">006507</idno><idno type="wicri:Area/Main/Exploration">006507</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Comparison of Sinemet CR4 and standars Sinemet: double blind and long-term open trial in Parkinsonian patients with fluctuations</title><author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J." last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author><author><name sortKey="Schwartz, K" sort="Schwartz, K" uniqKey="Schwartz K" first="K." last="Schwartz">K. Schwartz</name></author><author><name sortKey="Vander Linden, C" sort="Vander Linden, C" uniqKey="Vander Linden C" first="C." last="Vander Linden">C. Vander Linden</name></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="1989">1989</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chemotherapy</term><term>Comparative study</term><term>Controlled release form</term><term>Degenerative disease</term><term>Dopa</term><term>Dosage form</term><term>Drug combination</term><term>Human</term><term>Nervous system diseases</term><term>Oral administration</term><term>Parkinson disease</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Carbidopa</term><term>Dopa</term><term>Association médicamenteuse</term><term>Forme libération contrôlée</term><term>Parkinson maladie</term><term>Homme</term><term>Chimiothérapie</term><term>Etude comparative</term><term>Forme pharmaceutique</term><term>Voie orale</term><term>Traitement</term><term>Maladie dégénérative</term><term>Système nerveux pathologie</term><term>Sinemet CR4</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">More sustained plasma levodopa levels may be achieved with a new controlled-release formulation of carbidopa/levodopa, Sinemet CR4. We studied 20 patients, with Parkinson's disease complicated by «wearing-off» phenomenon. In a 12-week double-blind study, the average number of tablets administered per day decreased from 5.7±1.2 to 3.8±0.7 when Sinemet CR4 (50/200) was substituted for the standard Sinemet (25/100)</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li></region><settlement><li>Houston</li></settlement><orgName><li>Baylor College of Medicine</li></orgName></list><tree><noCountry><name sortKey="Schwartz, K" sort="Schwartz, K" uniqKey="Schwartz K" first="K." last="Schwartz">K. Schwartz</name><name sortKey="Vander Linden, C" sort="Vander Linden, C" uniqKey="Vander Linden C" first="C." last="Vander Linden">C. Vander Linden</name></noCountry><country name="États-Unis"><region name="Texas"><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J." last="Jankovic">Joseph Jankovic</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006507 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006507 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:90-0045470
|texte= Comparison of Sinemet CR4 and standars Sinemet: double blind and long-term open trial in Parkinsonian patients with fluctuations
}}
| This area was generated with Dilib version V0.6.23. |  |